The exact duration of targeted drug treatment for liver cancer is uncertain. If the targeted drug is proved to be effective, patients need to take the drug for a long time until the disease progresses or drug resistance occurs. Targeted drugs for liver cancer are mainly used in the treatment of advanced hepatocellular carcinoma, and at present, commonly used in clinical practice are sorafenib, lenvatinib, regorafenib, etc. Patients with effective treatment need to take the drugs for a long period of time to control the progression of liver cancer, and only when the patients are resistant to the targeted drugs or can not tolerate the side effects of the drugs or the disease has progressed, can they stop taking the drugs and switch to other treatments. Targeted drugs for liver cancer often cause adverse reactions such as high blood pressure, bleeding, diarrhea, skin rash, etc. Therefore, its use must be guided by professional doctors and cannot be taken by oneself. During the period of using the drug, regular review is needed, and if there is any discomfort, consult the doctor in time to avoid delaying the condition.